Thornhill, Canada Clinical Trials

A listing of Thornhill, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 181 clinical trials
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301)

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be …

bevacizumab
carboplatin
measurable disease
topotecan
gemcitabine
Sunnybrook Health Sciences Centre
 (7.2 away) Contact site
  • 3 views
  • 29 Oct, 2022
  • +112 other locations
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the body (metastatic); has a certain type of abnormal gene called "BRAF"; and has not …

bevacizumab
BRAF
cetuximab
primary cancer
metastasis
Sunnybrook Health Sciences Centre
 (7.2 away) Contact site
  • 0 views
  • 28 Oct, 2022
  • +329 other locations
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin) (ADjoin)

This 110-week study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

eczema
topical agents
progestogen
hormonal contraception
atopy
North York Research Inc.
 (3.5 away) Contact site
  • 626 views
  • 28 Oct, 2022
  • +257 other locations
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 …

Investigational Site Number :1240001
 (6.2 away) Contact site
  • 3 views
  • 20 Jan, 2023
  • +118 other locations
A Phase 4, Randomized, Double-blind, Placebo-controlled,Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma (MORPHEO)

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

Investigational Site Number :1240005
 (10.1 away) Contact site
  • 4 views
  • 23 Dec, 2022
  • +51 other locations
Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine (RILECSU)

The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria …

Investigational Site Number :1240005
 (10.1 away) Contact site
  • 8 views
  • 27 Jan, 2023
  • +40 other locations
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

This is a parallel, treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18 years) with moderate-to-severe AD and intolerance or inadequate response to topical corticosteroids (TCS). In parallel …

topical corticosteroid
eczema
topical agents
corticosteroids
Investigational Site Number :1240007
 (8.0 away) Contact site
  • 18 views
  • 27 Jan, 2023
  • +28 other locations
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis (COMBAT-ALS)

A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12 months followed by a 6-month open-label extension phase.

riluzole
pulmonary function test
edaravone
swallow study
ibudilast
Sunnybrook Research Institute
 (7.2 away) Contact site
  • 57 views
  • 18 Oct, 2022
  • +22 other locations
Inspiratory Muscle Training in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and COVID-19 Survivors (Inspire ME)

Coronavirus-2019 (COVID-19) is a viral disease leading to respiratory dysfunction, but it may also affect the brain and result in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This may be the result of the COVID-19 virus infecting regions of the brain responsible for respiratory control. The symptoms of COVID-19 …

covid-19
fatigue
Accepts healthy volunteers
exercise stress test
coronavirus
York University
 (3.0 away) Contact site
  • 9 views
  • 18 Oct, 2022
  • 1 location
ODYSSEE-vCHAT Pilot Trial: A Virtual Community Promoting Health Literacy, Self-Care, and Peer Support for Heart Failure (ODYSSEE-vCHAT)

INTRODUCTION Psychological distress and reduced quality of life are prevalent within the heart failure (HF) population. The 1-year rehospitalization (40%) and 5-year mortality (45% for women and 60% for men) rates are high. International task force committees report that medical therapy combined with counselling for HF self-care optimizes clinical outcomes. …

heart failure
chronic heart failure
ventriculogram
systolic heart failure
ejection fraction
Sunnybrook Health Sciences Centre
 (7.2 away) Contact site
  • 0 views
  • 19 Oct, 2022
  • +2 other locations